Seres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Decrease in Short Interest

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 763,100 shares, a decline of 95.2% from the March 31st total of 16,010,000 shares. Approximately 12.0% of the shares of the company are sold short. Based on an average daily volume of 70,300 shares, the short-interest ratio is presently 10.9 days.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Avantax Advisory Services Inc. increased its stake in Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 28,500 shares during the last quarter. Jane Street Group LLC grew its position in Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 37,866 shares during the last quarter. Virtu Financial LLC boosted its stake in shares of Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 18,191 shares during the period. Northern Trust Corp boosted its position in Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock valued at $218,000 after buying an additional 44,461 shares during the period. Finally, State Street Corp grew its stake in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after purchasing an additional 43,700 shares during the last quarter. Hedge funds and other institutional investors own 59.34% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on MCRB. StockNews.com upgraded shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of Seres Therapeutics in a report on Thursday, March 20th. Finally, The Goldman Sachs Group reduced their price objective on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a report on Friday, March 14th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, Seres Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $80.00.

Seres Therapeutics Trading Up 11.0 %

Shares of NASDAQ MCRB traded up $1.00 during mid-day trading on Friday, hitting $10.08. The company had a trading volume of 272,001 shares, compared to its average volume of 161,133. Seres Therapeutics has a 1 year low of $7.18 and a 1 year high of $30.60. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -43.82 and a beta of 2.54. The stock's 50-day moving average price is $12.99 and its 200-day moving average price is $15.17.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.